Compound Danshen Dropping Pills
Phase 3Small molecule
Compound Danshen Dropping Pills is one of 26 small molecule programs targeting Microcirculation. It is currently in Phase 3.
2
Indications
3
Total Trials
1
Active Trials
25
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
25 competitors in AIDS
#DrugCompanyPhaseTrials
1Norvir
AbbVieApproved
Thalomid
Bristol-Myers SquibbApproved
Aralen
SanofiApproved
Tivicay
GSKApproved
Vemlidy
GileadApproved
Emtriva
GileadApproved
Tybost
GileadApproved
Andriol
AAuxilium
Approved
Epivir
GGlaxo Dba Glaxosmithkline
Approved
Implanon
OOrganon and Co
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Myocardial Infarction1 trial
The Impact of Compound Danshen Dropping Pills (CDDP) on the Post-myocardial Infarction Ventricular Remodeling
Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 4·NCT05000411·268 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- RRuijin Hospital